Velcade, Thalidomide, Dexamethasone — Competitive Intelligence Brief

Velcade, Thalidomide, Dexamethasone (Velcade, Thalidomide, Dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

phase 3 Proteasome inhibitor Proteasome Oncology Small molecule

Target snapshot

Velcade, Thalidomide, Dexamethasone (Velcade, Thalidomide, Dexamethasone) — University of Arkansas. Velcade (bortezomib) is a proteasome inhibitor that blocks the action of proteasomes, which are complexes that break down proteins in cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Velcade, Thalidomide, Dexamethasone TARGET	Velcade, Thalidomide, Dexamethasone	University of Arkansas	phase 3	Proteasome inhibitor	Proteasome
Ninlaro	IXAZOMIB	Takeda	marketed	Proteasome Inhibitor	Proteasome subunit beta type-5	2015-01-01
Kyprolis	carfilzomib	Amgen	marketed	Proteasome Inhibitor [EPC]	Proteasome subunit beta type-5	2012-01-01
Velcade	bortezomib	Shilpa	marketed	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
Drug: Carfilzomib + Dexamethasone	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
Kyprolis	Kyprolis	Black Sea Hematology Association	marketed		Cathepsin B, Glutathione S-transferase omega-1, Proteasome subunit beta type-10
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-11-03 — Velcade · 8962572 · Formulation · US
• 2042-09-23 — Velcade · 11752164 · Method of Use · US
• 2042-09-23 — Velcade · 11679119 · Method of Use · US
• 2042-09-23 — Velcade · 12005069 · Formulation · US

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class